ASH Summit on Immunotherapies for Hematologic Diseases

March 2-3, 2023
Omni Shoreham Hotel, Washington, DC

Why is the success of immunotherapies and other targeted therapies such as gene therapy so variable within different patient populations? How can we improve these targeted therapies for widespread use in patients with hematologic diseases? Help answer these questions and more at the ASH Summit on Immunotherapies for Hematologic Diseases.

This in-person Summit is a unique meeting of the minds, bringing together academic, medical, industry, and federal regulatory communities to address the obstacles in immunotherapy treatment development for classical and malignant hematologic conditions. Whether you’re an established academic investigator, trainee, practicing clinician, industry researcher, or federal regulator, you won’t want to miss this unique opportunity to share ideas! Through participation in this meeting, attendees will be able to: 

Discuss fundamental advances in basic immunology that provide the foundation for immune therapies and their application
Gain insights into critical limitations of immunotherapies and gene therapy including associated adverse events
Examine cellular and molecular mechanisms involved in resistance and relapse associated with these therapies
Review new immunotherapy targets
Discuss the application of CRISPR gene editing in the development of targeted therapies
Analyze cell manufacturing considerations
Learn about the application of immunotherapies for the treatment of both classical hematologic and malignant diseases

Target Audience

The ASH Summit on Immunotherapies for Hematologic Diseases is designed to provide a wide set of learning and networking opportunities for experts in hematology, including:

Laboratory-based scientists
Translational and clinical researchers
Practitioners interested in the application of immunotherapies
Young investigators (trainees)
Cellular therapy, gene therapy, biopharmaceutical, and life sciences industry experts
Regulatory scientists

View abstract categories

Summit Abstracts

Full abstract text will be available to registered attendees via the mobile app. In accordance with the event’s embargo guidelines, for poster presentations, the embargo lifts when the poster hall containing the poster opens for viewing and for oral/invited presentations, the embargo lifts at the start time of the session in which the presentation is being made.

Close All Open All

Abstract #	Title	Presenter	Presentation
1	HMGA1 Chromatin Regulators Drive Immune Evasion in MPN Progression through Epigenetic Rewiring to Repress Networks Involved in Antigen Presentation	Joseph Kim	Oral
2	Safety and Anti-Leukemic Activity of CD123-CAR T Cells in Pediatric Patients with AML: Preliminary Results from a Phase 1 Trial	Swati Naik	Oral
3	Tgfß-Imprinting of Primary NK Cells Decreases CD38-Nadase, Promotes a Tissue-Resident Addressin Profile, and Improves Cytotoxicity and Metabolism	Marcelo Pereira	Oral
4	Rhoa Inactivation As a Driver of CAR-T Therapy Resistance in Diffuse Large B-Cell Lymphoma	Austin D. Newsam	Oral
5	Tunable Activation of CD19-CART Results in Enhanced Metabolic Activity and Cytotoxicity Against Antigen-Low Leukemia	Mehdi Benzaoui	Oral
6	Evaluation of CD38KO/CD38-CAR Human Primary Natural Killer Cells Against CD38-Expressing Hematologic Malignancies	Ella C. Troy	Oral
LBA - 1	Cord Blood-Derived CD19-Specific Chimeric Antigen Receptor T Cells: An Off-the-Shelf Promising Therapeutic Option for Treatment of Diffuse Large B-Cell Lymphoma	Tiantian Yu	Oral
7	Deletion of AMPK Reduces Oxidative Metabolism in Gvhd-Causing Human T Cells	Archana Ramgopal	Poster & Rapid Fire Talk
8	Novel Therapeutic Strategies to Overcome Hyperthermia-Induced Metabolic Dysfunction of CAR-T Cells	Taisuke Kondo	Poster & Rapid Fire Talk
9	Use of a Foamy-Virus Vector System to Produce an ‘Off-the-Shelf’ Fcγ-CR-T Cell Product for the Treatment of Hematological and Solid Tumor Malignancies	Ioanna Lazana	Poster & Rapid Fire Talk
10	Multiple Myeloma & Severe Sars-Cov-2: Delving into the Immunological Paradigm with a Promising Cellular Therapeutic Intervention	Yan Leyfman	Poster
11	The Roles and Challenges of Advanced Therapies in the Management of Refractory Immune Thrombocytopenia: A Case Report and Review of Literature	Beatrice Torere	Poster
12	Correlations between Overall Response Rate, Progression-Free Survival and Overall Survival with Belantamab Mafodotin in Refractory or Relapsed Multiple Myeloma	Nosakhare Ilerhunmwuwa	Poster
13	A Retrospective Study of Clinical Outcomes in Patients with Non-Hodgkin Lymphoma with Secondary Central Nervous System Involvement after CD19 CAR-T Therapy	Aseel Alsouqi	Poster & Rapid Fire Talk
14	Longitudinal Geriatric Assessment in Older Patients with Relapsed Refractory, Large B-Cell Lymphoma Receiving CAR T-Cell Therapy: A Prospective Pilot Study	Richard Lin	Poster & Rapid Fire Talk
15	Hemophagocytic Lymphohistiocytosis As a Complication of CAR-T Cell Therapy: A Case Report	Flavia Gava	Poster
16	Outcomes of Myeloid Sarcoma: A 10-Year Institutional Study	Kriti Gera	Poster
17	Visualizing CAR-T Cell Trafficking Using the NIS Reporter	Brynn Duncan	Poster & Rapid Fire Talk
18	Bridging the Gap of Healthcare Access: Utilizing an Ontology Platform to Connect BALT Patients with COVID-19 to Active Immunotherapeutic Clinical Trials	Yan Leyfman	Poster
19	Viral Escape in Cytomegalovirus Viral-Specific T Cell Therapy Resistance	John Idso	Poster
LBA-2	The CLEC2D/CD161 Axis As a Novel Ligand/Receptor Pathway for Immunotherapeutic Intervention in CLEC2D+Hematological Malignancies	Shruti Malu	Poster

Abstract Winners

Joseph Kim Johns Hopkins University School of Medicine	HMGA1 Chromatin Regulators Drive Immune Evasion in MPN Progression through Epigenetic Rewiring to Repress Networks Involved in Antigen Presentation
Brynn B. Duncan, MD National Heart, Lung, and Blood Institute, National Institutes of Health	Visualizing CAR-T Cell Trafficking Using the NIS Reporter
Austin D. Newsam, BS University of Miami Miller School of Medicine	Rhoa Inactivation As a Driver of CAR-T Therapy Resistance in Diffuse Large B-Cell Lymphoma
Taisuke Kondo, PhD National Institutes of Health	Novel Therapeutic Strategies to Overcome Hyperthermia-Induced Metabolic Dysfunction of CAR-T Cells
Aseel Alsouqi, MD University of Pittsburgh Medical Center	A Retrospective Study of Clinical Outcomes in Patients with Non-Hodgkin Lymphoma with Secondary Central Nervous System Involvement after CD19 CAR-T Therapy

Program Schedule

Close All Open All

7:00 a.m. Hampton Ballroom	Breakfast/Exhibits Open
8:15 a.m. Blue Room	Keynote Address Chair: Shannon Maude, MD, PhD University of Pennsylvania Philadelphia, PA Speaker: T cell Therapies for Patients with Blood Disorders: Broadening Applicability Catherine Bollard, MD, MBChB Children's National Hospital Washington, DC
9:00 a.m. Blue Room	The Science of Immunotherapy Chairs: Antonio Risitano, MD, PhD University of Naples Naples, Italy Madhav Dhodapkar, MBBS Emory University Atlanta, GA Speakers: Personalized Immune Based Strategies in Cancer Catherine Wu, MD Dana-Farber Cancer Institute Boston, MA The Future of Science of Cancer Immunotherapy Ira Mellman, PhD Genentech New York, NY Uncertain Mechanisms of Action of Successful Biologics - ATG Focus Phillip Scheinberg, MD Hospital A Beneficênica Portuguesa de São Paulo São Paulo, Brazil
10:55 a.m. Blue Room	Use of Immunotherapies in Clinical Practice or Trials Chairs: Katy Rezvani, MD The University of Texas MD Anderson Cancer Houston, TX Sarah Cooley, MD Fate Therapeutics, Inc. San Diego, CA Speakers: Chimeric Antigen Receptor (CAR) Engineering Beyond T-Cells Dean Lee, MD, PhD The Research Institute At Nationwide Children’s Hospital Columbus, OH T-Cell Engineering Beyond CAR Aude Chapuis, MD Fred Hutchinson Cancer Research Center Boston, MA
12:00 p.m. Hampton Ballroom	Lunch/Exhibits Open
1:00 p.m. Blue Room	Use of Immunotherapies in Clinical Practice or Trials (Continued) Chairs: Katy Rezvani, MD The University of Texas MD Anderson Cancer Houston, TX Sarah Cooley, MD Fate Therapeutics, Inc. San Diego, CA Speakers: Bispecific Antibodies in Hemophilia Stacy Croteau, MD Children's Hospital Boston Boston, MA Presentation from the Chinese Society of Hematology: BCMA CART in China and Beyond Chengcheng Fu, MD, PhD The First Affilliated Hospital of Soochow University Suzhou, CHN
2:30 p.m. Blue Room	Mechanisms of Resistance to Immunotherapies Chairs: Rodrigo Calado, MD, PhD University of São Paulo São Paulo, Brazil Loretta Nastoupil, MD The University of Texas MD Anderson Cancer Center Houston, TX Speakers: Initial Treatment Failure Robbie Majzner, MD Stanford University Stanford, CA Relapse Associated with Late Immunotherapy Failure Nirali Shah, MD National Cancer Institute Bethesda, MD Targeting Innate Immunity: Anti-Complement Therapies Eleni Gavriilaki, MD, PhD George Papanicolaou General Hospital Thessaloniki, Greece
4:55 p.m. Blue Room	Cell Manufacturing Considerations: Transitioning from Early to Late Phase Trials to Licensure Chairs: Catherine Bollard, MD, MBChB Children's National Hospital Washington, DC Terry Fry, MD University of Colorado School of Medicine Aurora, CO Speakers: Academia Perspective: Challenges in the Academia Setting to Take Novel Platforms into the Clinic - How Have They Approached IND Filings (gene editing) Isabelle Riviere, PhD Memorial Sloan Kettering Cancer Center New York, NY Industry Perspective: Challenges in the Industry Setting; Dealing with Adverse Events (from a GMP Perspective) Gwen Binder, PhD Cabaletta Bio Philadelphia, PA The Regulatory Perspective: Cell Manufacturing Considerations Andrew Timmons, PhD US Food and Drug Administration Washington, DC Tunable Activation of CD19-CART Results in Enhanced Metabolic Activity and Cytotoxicity Against Antigen-Low Leukemia Mehdi Benzaoui National Cancer Institute Bethesda, MD
6:40 p.m. Blue Pre-Function Room	Welcome Reception and Poster Presentations

8:00 a.m. Hampton Ballroom	Breakfast/Exhibits Open
9:00 a.m. Blue Room	Emerging Strategies to Overcome Current Immunotherapy Limitations Chairs: David Scott, PhD Uniformed Services University of Health Sciences Bethesda, MD Frederick Locke, MD H. Lee Moffitt Cancer Center and Research Institute Tampa, FL Speakers: Emicizumab and ITI: Partners or Foes Shannon Meeks, MD, MBA Emory University Atlanta, GA Improving CAR T By Promoting Intracellular and Extracellular Signaling Marcela Maus, MD, PhD, Massachusetts General Hospital Harvard Medical School Boston, MA Genome Editing for Adoptive T Cell Therapy Chiara Bonini, MD Ospedale San Raffaele Milan, Italy
11:00 a.m. Blue Pre-Function Room	Poster Presentations
12:00 p.m. Hampton Ballroom	Lunch/Exhibits
1:00 p.m. Blue Room	Immunotherapy Toxicities – Prediction and Management Chairs: Jae Park, MD Memorial Sloan-Kettering Cancer New York, NY Rayne Rouce, MD Clinical Care Center-Texas Children's Hospital Houston, TX Speakers: Cytokine Release Syndrome David Teachey, MD Children's Hospital of Philadelphia Philadelphia, PA Neurotoxicity Juliane Gust, MD, PhD Seattle Children's Hospital Seattle, WA Off-Target Effects of Immunotherapy Elad Sharon, MD, MPH Cancer Therapy Evaluation Program Bethesda, MD
2:55 p.m. Blue Room	Late Breaking Special Session (ASH-SITC JOINT Session) Chairs: John Tisdale, MD NIH Molecular & Clinical Hematology Bethesda, MD Nina Shah, MD University of California San Diego San Diego, CA Speakers: The Immune Predictors of Response to CAR T and Bispecific T Cell Therapy Paola Neri, MD, PhD University of Calgary Calgary, Canada Novel Technologies to Improve and Safely Deliver Gene Therapies Jennifer E. Adair, PhD Fred Hutchinson Cancer Center Boston, MA Cord Blood-Derived CD19-Specific Chimeric Antigen Receptor T Cells: An Off-the-Shelf Promising Therapeutic Option for Treatment of Diffuse Large B-Cell Lymphoma Tiantian Yu, PhD The Second Affiliated Hospital of Nanchang University Nanchang, China

View the Schedule at-a-Glance for additional details on the Summit’s program.

2023 Program Co-Chairs

Shannon Maude, MD, PhD, Children’s Hospital of Philadelphia
Terry Fry, MD, University of Colorado School of Medicine and Sana Biotechnology
Neal Young, MD, National Institutes of Health

ASH Summit Steering Committee

Catherine Bollard, MD, Children’s National Medical Center 
Rodrigo Calado, MD, PhD, University of Sao Paulo 
Sarah Cooley, MD, MS, Fate Therapeutics 
Madhav Dhodapkar, MD, Emory University 
Stephen Forman, MD, City of Hope 
Frederick Locke, MD, Moffitt Cancer Center 
Loretta Nastoupil, MD, MD Anderson Cancer Center 
Jae Park, MD, Memorial Sloan Kettering Cancer Center 
Katy Rezvani, MD, PhD, Anderson Cancer Center 
Antonio Risitano, MD, PhD, University of Naples 
David Scott, MS, PhD, Uniformed Services University of Health Sciences 
Guy Young, MD, Children’s Hospital of Los Angeles

Questions?

For questions about the program for the 2023 ASH Summit on Immunotherapies for Hematologic Diseases, please contact ASH Deputy Director of Scientific Affairs Alice Kuaban at [email protected].

For general inquiries about this meeting, please submit them to [email protected].

91��Ʒ

Meetings